Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v12-EN | Version v9-EN | |
---|---|---|
Language | English | English |
Date Updated | 2020-05-29 | 2020-05-16 |
Drug Identification Number | 02403196 | 02403196 |
Brand name | ACT CLARITHROMYCIN XL | ACT CLARITHROMYCIN XL |
Common or Proper name | CLARITHROMYCIN FC TABLETS 500MG | CLARITHROMYCIN FC TABLETS 500MG |
Company Name | TEVA CANADA LIMITED | TEVA CANADA LIMITED |
Ingredients | CLARITHROMYCIN | CLARITHROMYCIN |
Strength(s) | 500MG | 500MG |
Dosage form(s) | TABLET (EXTENDED-RELEASE) | TABLET (EXTENDED-RELEASE) |
Route of administration | ORAL | ORAL |
Packaging size | 60 | 60 |
ATC code | J01FA | J01FA |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for shortage | Shortage of an active ingredient. | Shortage of an active ingredient. |
Anticipated start date | ||
Actual start date | 2020-05-15 | 2020-05-15 |
Estimated end date | 2020-06-30 | 2020-08-31 |
Actual end date | 2020-05-27 | |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | Allocating to 100% of our market. | Allocating to 100% of our market. |
Health Canada comments |